About AMX0114 AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2 (CAPN2) for the potential treatment of ALS. The U.S. Food and Drug Administration (FDA) has granted AMX0114 Fast Track designation for the treatment of ALS. In preclinical studies, treatment with AMX0114 resulted in potent, dose-dependent, and durable reduction in CAPN2 mRNA and calpain-2 protein levels in disease-relevant cell models of axonal degeneration. This translated to improved neuronal survival, including in a model of TDP-43 ALS, and reductions in extracellular neurofilament light (NfL) levels across multiple disease models and paradigms of neuronal injury. AMX0114 was well-tolerated in in vivo preclinical safety studies.
Citi analyst Geoff Meacham initiated coverage of Amylyx (AMLX) with a Buy rating and $12price target“There is a lot to like” within the company’s pipeline, with three assets spanning four indications that range from early to late-stage studies, and several key catalysts throughout 2025 and into the first half of 2026 “that provide optionality at various timepoints,” the analyst tells investors in a research note. The firm says all four indications being pursued by Amylyx are in areas of significant high unmet need. Of the company’s ongoing Phase 2 and later studies, “clear and well-established clinical endpoints provide a direct read to probability of success and approval,” contends Citi.
Research analysts at Guggenheim initiated coverage on shares ofAmylyx Pharmaceuticals (NASDAQ:AMLX-Get Free Report)in a research note issued to investors on Tuesday,\ The firm set a "buy" rating and a $17.00 price target on the stock. Guggenheim's price objective points to a potential upside of 238.65% from the company's previous close.
Copper looking decent today but hard to know what to play given they are mostly just below resistance. I still have a ton of III and rebought ERO as a trade. SURG dropped a touch today but unclear what it will do here. Sitting on a ton of cash but not a lot jumping out at me. ARG maybe but the lows today were a better entry point. At some point the Golds will get attractive again because Gold itself is still a really nice price for them. I am looking at Equinox Gold. If the Silver stocks drop enough they get interesting again I don't think the bull in Silver is over. The war however is distracting from the tariff story which could get these commodities rolling at some point.
Company Profile Reborn Coffee, Inc., through its subsidiaries, operates and franchises retail locations, kiosks, and cafes that focus on serving specialty-roasted coffee in California and Europe. It purchases, roasts, and sells coffee, tea and other beverages, and various food items. It offers products in various form factors, such as whole bean roasted coffee bags, single-serve drip bags, pour over packs, and cold brew concentrates. The company also offers its products online. Reborn Coffee, Inc. was founded in 2014 and is based in Brea, California.
Reborn Coffee says company-operated store average sales up 32% in Q2-to-date » 13:53 REBN Reborn Coffee announced… Reborn Coffee reports positive store-level sales trend in Q2 » 08:40 REBN REBN Reborn Coffee, Inc. $2.69 0.33(+13.98%)3:02 PM 06/24/25
I'm seeing a lot of bad press related to the manufactured home space. https://www.wkrn.com/news/local-news/antioch-trailer-park-neighbors-send-petition-to-property-owner/ I wonder if it will impact Clayton -> BRK?
NYSE - Nasdaq Real Time Price•USD Montrose Environmental Group, Inc.(MEG) TA-WATCH-! $21.82 +0.64 (+3.00%) As of 3:31:30 PM EDT. Market Open. ST Target-$23.50 MT Target-$27.00
Rezolute ticks higher following disclosure of CFO stock buy RZLT+5.71% 5,000 @ $4.05 6/24 Company Profile Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. RZLT Rezolute, Inc. $4.28 0.25(+6.20%)3:37 PM 06/24/25